{"id":469124,"date":"2021-03-31T16:33:34","date_gmt":"2021-03-31T20:33:34","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=469124"},"modified":"2021-03-31T16:33:34","modified_gmt":"2021-03-31T20:33:34","slug":"kyowa-kirin-integrates-north-america-businesses-in-support-of-companys-2030-vision-and-rapid-growth-trajectory","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kyowa-kirin-integrates-north-america-businesses-in-support-of-companys-2030-vision-and-rapid-growth-trajectory\/","title":{"rendered":"Kyowa Kirin Integrates North America Businesses in Support of Company’s 2030 Vision and Rapid Growth Trajectory"},"content":{"rendered":"
\n

New Organizational Structure and Senior Leadership Hires Seek to Strengthen Regional Business Operations, Optimize Investments and Aid in Delivery of First-in-Class Medicines<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n BEDMINSTER, N.J.<\/span>, March 31, 2021<\/span> \/PRNewswire\/ — Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a global specialty pharmaceutical company, today announced a key milestone in its North American Business Integration (NABI) initiative; specifically, the merger of its Kyowa Kirin Research and Kyowa Kirin Development companies into Kyowa Kirin, Inc. The outcome of this merger is a simpler business structure for the organization and a common set of processes and systems to enhance the productivity and collaborations across North America<\/span> discovery, development and commercial functions. This new structure will enable the region’s continued rapid growth and contributions toward the global organization’s New 2030 Vision, with a steady focus on creating and delivering novel medicines for patients.<\/p>\n

All organizational changes under the NABI initiative take effect on April 1, 2021<\/span>. Kyowa Kirin Canada, Inc. and BioWa, Inc., both maintain their current structure as subsidiaries of Kyowa Kirin, Inc. and Kyowa Kirin USA<\/span> Holdings, Inc. respectively. A management agreement between Kyowa Kirin, Inc. and each subsidiary provides for access to key business services.<\/p>\n

“We’ve received several FDA approvals since 2018 and continue to see great promise in our late-stage global pipeline. The organizational changes we are making through NABI will help Kyowa Kirin North America deliver the full value of these opportunities,” says Gary Zieziula<\/span>, President, Kyowa Kirin North America. “Through NABI, we’re working to enable more efficient collaborations and business support for the functions that discover, develop and deliver first-in-class medicines that can have a profound impact on patients’ lives.”<\/p>\n

\n

\n<\/p><\/div>\n

Between 2017 and 2020, annual revenues from KKNA medicines have grown from $25M<\/span> to more than $500M<\/span>. The NABI initiative will further serve KKNA in its rapid growth and expansion into new markets, including Canada<\/span>, and is aligned with Kyowa Kirin’s global priorities to:<\/p>\n